This product is a central anticholinergic anti-Parkinson's disease drug that selectively blocks the cholinergic nerve pathways in the striatum, but has less effect on the periphery, thus helping to restore the balance of dopamine and acetylcholine in the brain of Parkinson's patients and improve the patients' Parkinson's disease symptoms.

This product is a dopamine 2 (D2) receptor antagonist, and also has a 5-hydroxytryptamine 4 (5-HT4) receptor agonist effect, and has a mild inhibitory effect on 5-HT3 receptors. It can act on dopamine receptors in the medullary emetic chemoreceptor zone (CTZ) to increase the threshold of CTZ, and has a strong central antiemetic effect. This product can also block hypothalamic dopamine receptors, inhibit prolactin inhibitory factor, and promote the secretion of prolactin, so it has a certain lactation effect. The inhibitory effect on other parts of the central nervous system is relatively small, with a weak sedative effect and less hypnotic effect. The effect on the gastrointestinal tract is mainly in the upper digestive tract, promoting the movement of the stomach and upper intestinal segments; increasing the tension of the gastrointestinal sphincter in the resting state, increasing the tension and contraction amplitude of the lower esophageal sphincter, and increasing the pressure at the lower end of the esophagus.

It mainly acts on H2 receptors on parietal cells, competitively inhibiting histamine. It can inhibit basal gastric acid secretion, as well as gastric acid secretion stimulated by food, histamine, pentagastrin, caffeine and insulin.

It mainly acts on H2 receptors on parietal cells, competitively inhibiting histamine. It can inhibit basal gastric acid secretion, as well as gastric acid secretion stimulated by food, histamine, pentagastrin, caffeine and insulin.